



COVID-19 Clinical Care

Jonathan Vilasier Iralu, MD, FACP
Indian Health Service Chief Clinical Consultant
for Infectious Diseases



Disclosures



Testing update

- ❖ Preferred reference lab test is the naso-pharyngeal swab PCR assay
- ❖ Cepheid Xpert nucleic acid amplification assay just arriving now at IHS sites
- ❖ Abbott ID NOW COVID-19 device has arrived at some IHS sites
- ❖ qSARS-CoV-2 IgG/IgM Rapid Test (Cellex): FDA EUA
 - ❖ Lateral flow immunoassay strip with bands for IgG and IgM: 10-20 minute turn around



Clinical Presentation Update

Neurologic manifestations of COVID-19 in ARDS

(Mao et al, Jama Neuro, 4/20/20)

- ❖ **214 COVID patients with ARDS** at Huazhong U in Wuhan, China
 - ❖ Mean age 52.7 years, 40.7% male, 41% severe, 59% nonsevere
 - ❖ 36.4% had neurologic manifestations
 - ❖ Dizziness, headache, smell/taste impairment common in all
 - ❖ Comparison of **severe c/w non-severe pneumonia** patients
 - ❖ Cerebrovascular Disease 5.7% vs 0.8%
 - ❖ Impaired Consciousness 14.8% vs 2.4%
 - ❖ Skeletal muscle injury 19.3% vs 4.8%



Clinical Presentation Update

Coagulopathy and Antiphospholipid Abs in COVID 19

(Zhang et al, NEJM, 4/8/2020)

- ❖ Initial case report of 69 yo male with COVID-19
 - ❖ Leukocytosis, thrombocytopenia, elevated PT and PTT present
 - ❖ Positive anticardiolipin IgA, anti-Beta2 glycoprotein I IgA and IgG
- ❖ Two more patients identified with identical findings
- ❖ No Lupus anticoagulant detected
- ❖ All three patients had multiple cerebral infarctions



Treatment Update: Compassionate use Remdesivir with severe COVID-19

(Grein et al, NEJM 4/10/2020)

- ❖ 61 patients enrolled with O₂ sat \leq 94%
- ❖ **Remdesivir** 200 mg IV x 1 then 100 mg IV daily x 9 days
- ❖ 53 patients analyzed (57% on ventilators, 8% on ECMO)
 - ❖ 68% had improved oxygenation at median 18 days
 - ❖ 57% of intubated patients were extubated
 - ❖ 47% discharged home
 - ❖ 13% died

Need randomized, controlled trial data



IDSA COVID-19 Treatment guidelines

Released 4/11/2020

- ❖ Treatments recommended “only in the context of clinical trials”
 - ❖ Remdesivir
 - ❖ Hydroxychloroquine monotherapy
 - ❖ Hydroxychloroquine/Azithromycin
 - ❖ Lopinavir/ritonavir
 - ❖ Convalescent serum
 - ❖ Steroids for ARDS
- ❖ Recommended against steroids for pneumonia
 - “Knowledge gaps” abound*



More COVID-19 Training

- ❖ **CDC:** <https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html>
- ❖ **ACP Physician Handbook:** <https://www.acponline.org/clinical-information/clinical-resources-products/coronavirus-disease-2019-covid-19-information-for-internists>
- ❖ **U of Washington:** <https://covid-19.uwmedicine.org/Pages/default.aspx>
- ❖ **Brigham and Women's Hospital:** covidprotocols.org
- ❖ **IDSA:** <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>

